Hepatology Communications · 19 Nov 2026
Apixaban reduces hepatic decompensation in patients with cirrhosis (ApiHep): A randomized controlled trial
Ayush Agarwal, Sagnik Biswas, Arnav Aggarwal, Sarthak Saxena, Jasmita Dass, Melissa Glenda Lewis, Sonu Kumar, Shubham Jain, Shekhar Swaroop, Vishal Singh Chauhan, Ankit Agarwal, Mukul Aggarwal, Ashwani Kumar Mishra, Ankur Goyal, Shivanand Gamanagatti, Raju Sharma, Viren Sardana, Samagra Agarwal, Amit Yadav, Soumya Jagannath Mahapatra, Deepak Gunjan, Baibaswata Nayak, Shalimarh-index 49
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- OpenAlex0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background: Evolving data suggest that anticoagulation is safe in cirrhosis and may improve decompensation-free survival in select patients. This study aimed to assess the efficacy and safety of the direct oral anticoagulant apixaban in patients with cirrhosis. Methods: In this open-label randomized controlled trial with blinded endpoint assessment, adult patients (18–60y) with cirrhosis (Child-Pugh B7–C10) without splenoportal axis thrombosis were randomized (1:1) to receive apixaban (2.5 mg twice daily) along with standard medical therapy (SMT) or SMT alone for 12 months. The primary outcome was the comparison of the proportion of patients with hepatic decompensation at 1 year. Secondary outcomes included frequency of liver-related events, overall and liver-related mortality, and adverse events (AEs). Results: One hundred thirty-four patients (mean age 43.4±9.5 y; Child-Pugh B/C:115/19) were randomized (67 Apixaban+SMT and 67 SMT). Patients receiving apixaban experienced significantly lower rates of hepatic decompensation compared with SMT (33.1% vs. 54.3%; absolute risk reduction 21.2% [95% CI: 4.5%–38.2%]; p =0.013). Although rates of ascites (6.4% vs. 17.4%), HE (21.2% vs. 36.0%), and variceal bleeding (7.5% vs. 14.6%) were lower among patients receiving Apixaban+SMT as compared with SMT alone, the differences were not statistically significant. No significant between-group differences in all-cause and liver-related mortality at 1 year were noted. There were no significant between-group differences in AEs (55.2% vs. 53.7%), any bleeding (41.8% vs. 46.3%), and major bleeding (9.0% vs. 11.9%) events. Conclusions: Apixaban significantly reduced hepatic decompensation events without increasing hemorrhagic episodes in Child-Pugh B7-C10 cirrhosis (CTRI/2023/09/058018).
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Shalimar has the highest h-index among the authors (49).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (16)
What it cites, from open citation data, with Crossref's record of each.